Windlas IPO is one of the 4 Main Board IPOs going live on Aug 4, 2021.
Windlas Biotech IPO Summary
|IPO Opening Date
|Aug 4, 2021
|IPO Closing Date
|Aug 6, 2021
|Book Built Issue IPO
|₹5 per equity share
|₹448 to ₹460 per equity share
|Min Order Quantity
|[.] Eq Shares of ₹5
(aggregating up to ₹401.54 Cr)
|[.] Eq Shares of ₹5
(aggregating up to ₹165.00 Cr)
|Offer for Sale
|5,142,067 Eq Shares of ₹5
(aggregating up to ₹236.54 Cr)
-Windlas Biotech was Incorporated in 2001,
-It is one of India’s leading pharmaceutical formulations contract development and manufacturing organizations (CDMO) segments.
-The company offers CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products, including complex generics.
-It also sells its own branded products in the trade generics and OTC markets.
What do They do?
The business operates in 3 verticals;
1. CDMO Products and services,
2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products),
3. Export to other countries.
Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are other large pharmaceutical companies that are customers of Windlas Biotech.
Its manufacturing facilities are located at Dehradun, with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouches/ sachet, and 61.08 million liquid bottles.
- Leading market player in the domestic pharmaceutical formulation CDMO segment.
- Strong focus on the chronic therapeutic category.
- State-of-the-art manufacturing facilities in Dehradun, Uttarakhand.
- Professional and experienced Promoters and a senior management team.
- An innovative product portfolio of complex generic products.
- Robust financial performance track record.
|For the year/period ended (₹ in million)
|Profit After Tax
As the IPO is coming with other 3 companies it is highly certain that people are going to use funds wisely. The company can be good for long-term portfolio holders and can give good returns if you hold it for the long term.
No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on information published here. Any reader taking decisions based on any information published here does so entirely at its own risk. Investors should bear in mind that any investment in stock markets is subject to unpredictable market-related risks. The above information is based on RHP and other documents available as of date coupled with market perception. The author has no plans to invest in this offer.